Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – What’s Next?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $37.77, but opened at $40.00. Structure Therapeutics shares last traded at $39.4220, with a volume of 259,048 shares trading hands.

Wall Street Analysts Forecast Growth

GPCR has been the subject of several analyst reports. Canaccord Genuity Group initiated coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 target price for the company. Wolfe Research initiated coverage on shares of Structure Therapeutics in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. BMO Capital Markets set a $145.00 price target on shares of Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $109.25.

Structure Therapeutics Trading Up 0.7%

The firm has a 50 day moving average of $43.89 and a 200-day moving average of $57.21. The company has a market cap of $2.95 billion, a P/E ratio of -47.74 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. Equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GPCR. Morgan Stanley boosted its stake in Structure Therapeutics by 261.4% in the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after purchasing an additional 1,510,093 shares during the period. Wellington Management Group LLP boosted its stake in Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after purchasing an additional 1,432,797 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Structure Therapeutics by 477.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock worth $116,228,000 after acquiring an additional 1,381,745 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after acquiring an additional 1,150,000 shares during the last quarter. Finally, Capitolis Liquid Global Markets LLC bought a new stake in Structure Therapeutics in the 4th quarter worth approximately $61,086,000. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.